Eli Lilly has posted a solid set of figures for the second quarter, helped by price increases on several key drugs in the USA, and has raised its earnings guidance.

Net income was up 21% to $1.31 billion, while sales reached $5.29 billion, a rise of 3%. The most striking performances came from the antidepressant and fibromyalgia blockbuster Cymbalta (duloxetine), up 14% to $774.4 million and lung cancer treatment Alimta (pemetrexed) which shot up 40% to $385.3 million.

Lilly’s best-selling drug continues to be the antipsychotic Zyprexa (olanzapine), which had turnover of $1.20 billion, though that was down 3% on the like, year-earlier period despite a price rise. The insulin products Humalog and Humulin rose 9% and fell 9% respectively, to $477.5 million and $248.1 million.

The chemotherapy Gemzar (gemcitabine) was down 20% to $353.2 million, due to generic competition, while sales of the erectile dysfunction drug Cialis (tadalafil) were flat at $363.6 million. The osteoporosis drug Evista (raloxifene), which is also approved for the prevention of breast cancer for certain postmenopausal women, had revenues of $251.3 million, down 10%, while sales of Lilly’s other osteoporosis drug Forteo (teriparatide) were down 2% to $203.3 million.

The type 2 diabetes treatment Byetta (exenatide), which is sold in partnership with Amylin, had worldwide sales of $205.7 million, up 6%, and $114.6 million (+13%) of that was booked by Lilly. Strattera (atomoxetine) for attention deficit hyperactivity disorder, climbed 6% to $142.8 million, while Erbitux (cetuximab), the cancer agent that the company got hold of through its $6.5 billion acquisition of ImClone Systems last year, brought in $99.7 million.

Chief executive John Lechleiter said that Lilly did well, “notwithstanding the challenging global economic environment, " adding that movements in foreign exchange rates led to an improved gross margin. Noting that the firm has 66 molecules in clinical development, he added that the quarter saw Lilly receive “several important regulatory approvals”, most notably the bloodthinner Effient (prasugrel) in the USA.

Lilly raised its full-year earnings guidance to $4.20-$4.30 per share, from $4.00-$4.25 a share. It was a move that went down well with analysts who are now waiting to see how Effient performs.